On 30 July, VIVUS Inc. (NASDAQ:VVUS) reported Total revenue was $23.0 million in the current quarter, compared to $21.9 million in the second quarter of 2014. Of the total revenue, net product revenue was $14.0 million from sales of Qsymia in the current quarter, compared to $11.0 million in the second quarter of 2014.VIVUS Inc. (NASDAQ:VVUS) belongs to Healthcare sector. Its net profit margin is -75.20% and weekly performance is -24.86%. On last trading day company shares ended up $1.30. VIVUS Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -42.12%.
On 29 July, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis. Discovered by Arena, APD334 is an oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in ulcerative colitis as well as other autoimmune diseases. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved down -0.49% in last trading session and ended the day at $4.03. ARNA Gross Margin is 76.40% and its return on assets is -18.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -2.42%.
Baxalta Incorporated (NYSE: BXLT) announced that the Centers for Medicare and Medicaid Services (CMS) have expanded coverage to include in-home use of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], a treatment for adults with primary immunodeficiency (PI).On 05 August, Baxalta Incorporated (NYSE:BXLT) shares increased 0.54% and was closed at $37.30. Baxalta Incorporated (NYSE:BXLT) year to date (YTD) performance is 11.34%.
Exelixis, Inc. (NASDAQ:EXEL) announced that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company’s website. Exelixis, Inc. (NASDAQ:EXEL) ended the last trading day at $6.28. Company weekly volatility is calculated as 8.08% and price to cash ratio as 12.24. Exelixis, Inc. (NASDAQ:EXEL) showed a weekly performance of 12.14%.
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the company’s Board of Directors has declared a cash dividend of $0.43 per share of common stock for the third quarter of 2015. The dividend is payable on September 29, 2015, to stockholders of record at the close of business on September 16, 2015. Future dividends will be subject to Board approval. Gilead Sciences Inc. (NASDAQ:GILD) shares moved down -0.18% in last trading session and ended the day at $118.66. GILD Gross Margin is 86.50% and its return on assets is 42.70%. Gilead Sciences Inc. (NASDAQ:GILD) quarterly performance is 16.45%.